Placeholder Banner

BIO Elects New Board Directors and Re-Elects Section Governing Board Chairs

June 14, 2022
Media Contact
Karen Batra
202.449.6382

The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee directors for the 2022-2023 term.

BIO’s Board elections took place Monday, June 13 during the 2022 BIO International Convention hosted by BIO in San Diego, June 13-16, 2022.

“On behalf of our entire BIO organization, I want to congratulate our incoming Board directors and section leaders,” said Dr. Michelle McMurry-Heath, President & CEO of BIO. “This is a critical time for our industry. Our BIO Board – especially one as diverse and multi-faceted as this one – will help drive policies that keeps pace with innovation’s promise to cure disease, nourish society, and protect our planet.”

BIO’s Executive Committee directors for the 2022-2023 term are:

  • Paul Hastings, Nkarta Therapeutics – Board Chair/Health Section Chair
  • Elizabeth Lewis, Takeda Pharmaceuticals – Board Associate Vice Chair & Secretary
  • Bradford Zakes, Ceravast Medical – BIO Board Treasurer
  • Ted Love, Global Blood Therapeutics – Health Section Vice Chair
  • Sylvia Wulf, AquaBounty Technologies – Agriculture & Environment Section Chair
  • John Crowley, Amicus Therapeutics – Emerging Companies Section Chair
  • Jeremy Levin, Ovid Therapeutics – Immediate Past Chair
  • Erika Smith, ReNetX BIO – Emerging Companies Section Vice Chair
  • Anna Rath, Vestaron
  • Doug Doerfler, MaxCyte
  • Stuart Arbuckle, Vertex Pharmaceuticals
  • Christi Shaw, Kite, A Gilead Company
  • Bill Sibold, Genzyme, A Sanofi Company
  • Fritz Bittenbender, Genentech Roche
  • Chris Boerner, Bristol Myers Squibb
  • Eric Dube, Travere Therapeutics
  • Sue Washer, Applied Genetic Technologies Corporation (AGTC)
  • Aamir Malik, Pfizer
  • Jannie Oosthuizen, Merck
  • Victor Bulto, Novartis Pharmaceuticals
  • Bill Newell, Sutro BioPharma

Additional directors who were confirmed as the Executive Advisory Board (EAB) to the Executive Committee:

  • Ron Cohen, Acorda Therapeutics
  • Rachel King, former BIO Board Chair
  • John Maraganore, former BIO Board Chair
  • Richard Pops, Alkermes

Newly Elected to the BIO Health Section Governing Board (2022-2025 Term):

  • Jannie Oosthuizen, Merck

Newly Elected to the BIO Emerging Companies Section Governing Board (2022-2023 Term):

  • Pablo Cagnoni, Rubius Therapeutics
  • Kaye Foster, The Boston Consulting Group
  • Mike Huckman, Real Chemistry
  • Elizabeth Jeffords, Iolyx Therapeutics
  • Sheila Mikhail, Asklepios BioPharmaceutical

Newly Elected to the BIO Agriculture and Environment Section Governing Board (2022-2024 Term):

  • Angela Ailloni, Ginkgo Bioworks
  • Rocco Morelli, Recombinetics

Discover More
Washington, D.C. (October 3, 2022) – Today, a coalition of leading food and agriculture industry stakeholders in both Mexico and the United States released a new study revealing the broad impacts of Mexico’s proposed ban on biotech corn. The report,…
BIO is hosting the Impact Ag & Environment Conference, in-person for the first time in three years, in Omaha, Neb., Sept. 19-21, 2022. Headlined by Nebraska Gov. Pete Ricketts, the event will convene leaders across the bioeconomy whose…
The Biotechnology Innovation Organization today announced the opening of nominations for two awards to honor significant leaders driving cutting-edge, sustainable breakthroughs in the fields of agriculture and the environment.  The George…